Sign in
CompletedNo phase

Swab Testing to Optimize Pneumonia Treatment With Empiric Vancomycin

Key facts

Who runs it
Vanderbilt University Medical Center
Where
Nashville, United StatesSee the site
Trial code
Status
Completed
People taking part
277 people enrolled
Started
3 Apr 2024
Ended
27 Feb 2025
Type of study
Interventional, 2 groupsOne group gets an existing treatment, for comparison.
Treatments tested
  • MRSA Nasal Swab PCR
Record updated
27 February 2026

Who can take part

Age
18 years and older
Sex
Women and men
Healthy volunteers
Cannot take part

The registry criteria, word for word

Show all 6 criteriaShow less

Who can take part

  • Adult (age greater than or equal to 18) patients admitted/transferred to the Vanderbilt University Medical Center (VUMC) Medical Intensive Care Unit (MICU) from the VUMC Emergency Department or from a hospital floor within 48 hours of admission
  • Suspicion for pneumonia on admission (defined as an indication for antibiotics of "respiratory infection" and/or an order for a respiratory culture i.e., sputum culture, tracheal aspirate culture, or bronchoalveolar lavage (BAL) culture)
  • No topical nasal decolonization during hospitalization prior to collection of MRSA nasal swab PCR
  • Must match both of the following in either order:; The patient has been admitted to and physically located in the MICU; The patient has received a continuing vancomycin order, or a pharmacokinetics consult for a continuing vancomycin order, no later than 24 hours following their physical admission to the MICU

Who cannot take part

  • Hospital stay of longer than 48 hours prior to MICU admission
  • Known to be a prisoner

Where in United States

  • Vanderbilt University Medical CenterNashville, United States

About the trial

What the trial wants to find out

This is a single center, pragmatic, randomized clinical trial (pRCT) examining whether reporting the results of a negative rapid PCR back to the provider via a pager alert results in decreased vancomycin utilization for critically ill adults with community-acquired pneumonia when compared with usual care.

The 2 groups in the trial

  • No MRSA Nasal SwabNo study treatment, for comparison

    Subjects will not have a nasal swab collected.

  • MRSA Nasal SwabExisting treatment, for comparison

    Subjects will have a nasal swab collected and sent to the clinical laboratory for the MRSA nasal swab PCR test to be run. For the subjects assigned to the intervention group who have a negative MRSA nasal swab PCR result, providers will receive a pager alert which inform them of the negative result and will direct clinicians to clinical guidance recommending clinicians to discontinue vancomycin, if clinically appropriate.

    Treatment: MRSA Nasal Swab PCR

Data and sources

Registry record
Listed on ClinicalTrials.gov.How to verify a trial in the registry
Official title
Swab Testing to Optimize Pneumonia Treatment With Empiric Vancomycin (STOP-Vanc)
Publications
Record updated
27 February 2026